Chemokines as Biomarkers for Systemic Lupus Erythematosus
Author Information
Author(s): Jason W. Bauer, Emily C. Baechler, Michelle Petri, Franak M. Batliwalla, Dianna Crawford, Ward A. Ortmann, Karl J. Espe, Wentian Li, Dhavalkumar D. Patel, Peter K. Gregersen, Timothy W. Behrens
Primary Institution: Center for Immunology, University of Minnesota Medical School
Hypothesis
Type I IFN-regulated proteins are present in the serum of SLE patients and correlate with disease activity.
Conclusion
The study suggests that elevated serum chemokines may serve as biomarkers for disease activity in systemic lupus erythematosus.
Supporting Evidence
- 30 specific proteins were found at higher or lower levels in SLE-affected patients compared to controls.
- Most of the identified chemokines were inducible by type I IFN.
- Levels of serum chemokines correlated strongly with clinical measures of disease activity.
Takeaway
This study found that certain proteins in the blood of lupus patients can help doctors understand how active the disease is.
Methodology
The study measured serum levels of 160 proteins in SLE patients and healthy controls using protein microarrays.
Potential Biases
Potential bias in participant selection and the influence of confounding factors on protein levels.
Limitations
The study's findings need further validation in larger cohorts and clinical trials.
Participant Demographics
The study included 30 SLE patients and 15 healthy controls, with a predominance of African-American women among SLE patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website